Sustained demand for weight-loss and diabetes treatments has created prolonged supply shortages, compelling pharmaceutical developers to commit capital to contract manufacturing organization (CMO) capacity expansion. Multi-billion-dollar investments in fill-finish facilities are underway globally.
Supply Chain Diversification Initiatives
To hedge against single-site operational failures, drug manufacturers are decentralizing active pharmaceutical ingredient (API) production. Regulatory bodies have streamlined approval timelines for secondary manufacturing facilities to prevent market instability.